Hypera S.A (HYPE3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hypera S.A (HYPE3) has a cash flow conversion efficiency ratio of 0.014x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$200.76 Million ≈ $39.39 Million USD) by net assets (R$14.12 Billion ≈ $2.77 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HYPE3 equity to assets ratio to measure how much of total assets are equity-financed.
Hypera S.A - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Hypera S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Hypera S.A earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Hypera S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hypera S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bufab Holding AB
ST:BUFAB
|
0.064x |
|
Aura Minerals Inc
TO:ORA
|
0.571x |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
-0.412x |
|
Celldex Therapeutics Inc
NASDAQ:CLDX
|
-0.144x |
|
ABL Bio Inc
KQ:298380
|
0.179x |
|
California Water Service Group
NYSE:CWT
|
0.098x |
|
IHS Holding Ltd
NYSE:IHS
|
-8.679x |
|
Inner Mongolia First Machinery Group Co Ltd
SHG:600967
|
-0.041x |
Annual Cash Flow Conversion Efficiency for Hypera S.A (2006–2025)
The table below shows the annual cash flow conversion efficiency of Hypera S.A from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Hypera S.A stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | R$12.52 Billion ≈ $2.46 Billion |
R$1.43 Billion ≈ $280.27 Million |
0.114x | -45.65% |
| 2024-12-31 | R$12.10 Billion ≈ $2.37 Billion |
R$2.54 Billion ≈ $498.32 Million |
0.210x | +0.88% |
| 2023-12-31 | R$11.52 Billion ≈ $2.26 Billion |
R$2.40 Billion ≈ $470.14 Million |
0.208x | +8.72% |
| 2022-12-31 | R$10.66 Billion ≈ $2.09 Billion |
R$2.04 Billion ≈ $400.05 Million |
0.191x | +34.48% |
| 2021-12-31 | R$9.83 Billion ≈ $1.93 Billion |
R$1.40 Billion ≈ $274.53 Million |
0.142x | +11.14% |
| 2020-12-31 | R$9.24 Billion ≈ $1.81 Billion |
R$1.18 Billion ≈ $232.14 Million |
0.128x | +35.35% |
| 2019-12-31 | R$8.71 Billion ≈ $1.71 Billion |
R$823.88 Million ≈ $161.66 Million |
0.095x | -26.67% |
| 2018-12-31 | R$8.27 Billion ≈ $1.62 Billion |
R$1.07 Billion ≈ $209.27 Million |
0.129x | +7.03% |
| 2017-12-31 | R$7.74 Billion ≈ $1.52 Billion |
R$932.61 Million ≈ $183.00 Million |
0.121x | +19.04% |
| 2016-12-31 | R$8.71 Billion ≈ $1.71 Billion |
R$881.76 Million ≈ $173.02 Million |
0.101x | +151.20% |
| 2015-12-31 | R$8.03 Billion ≈ $1.58 Billion |
R$323.69 Million ≈ $63.51 Million |
0.040x | -54.62% |
| 2014-12-31 | R$7.48 Billion ≈ $1.47 Billion |
R$664.00 Million ≈ $130.29 Million |
0.089x | -5.57% |
| 2013-12-31 | R$7.08 Billion ≈ $1.39 Billion |
R$665.78 Million ≈ $130.64 Million |
0.094x | -9.50% |
| 2012-12-31 | R$6.87 Billion ≈ $1.35 Billion |
R$713.80 Million ≈ $140.06 Million |
0.104x | +19.04% |
| 2011-12-31 | R$6.65 Billion ≈ $1.30 Billion |
R$580.23 Million ≈ $113.85 Million |
0.087x | +556.93% |
| 2010-12-31 | R$5.06 Billion ≈ $992.69 Million |
R$67.24 Million ≈ $13.19 Million |
0.013x | -76.53% |
| 2009-12-31 | R$3.42 Billion ≈ $670.62 Million |
R$193.50 Million ≈ $37.97 Million |
0.057x | +25.23% |
| 2008-12-31 | R$1.92 Billion ≈ $376.06 Million |
R$86.64 Million ≈ $17.00 Million |
0.045x | -78.25% |
| 2007-12-31 | R$692.69 Million ≈ $135.92 Million |
R$143.97 Million ≈ $28.25 Million |
0.208x | +148.26% |
| 2006-12-31 | R$37.40 Million ≈ $7.34 Million |
R$-16.11 Million ≈ $-3.16 Million |
-0.431x | -- |
About Hypera S.A
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Co… Read more